{"id":819433,"title":"Archived 33: Summary of NACI statement of February 17, 2022: Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-03-10","captureTimestamp":"2026-03-10T17:27:16.107000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-novavax-nuvaxovid-covid-19-vaccine/summary-february-17-2022.html","snippet":"Archived 33: Summary of NACI statement of February 17, 2022: Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine Notice to reader This is an archived version. Please refer to current COVID-19 vaccine pages: NACI statements and publications COVID-19 vaccine: Canadian…","rawSnapshotUrl":"/api/snapshots/raw/819433","browseUrl":"https://replay.healtharchive.ca/job-7/20260310172716/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-novavax-nuvaxovid-covid-19-vaccine/summary-february-17-2022.html#ha_snapshot=819433","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}